The problem of amyloidosis continues to attract attention of scientists. Chronic infections can lead to development and progression of amyloidosis, and acute infections can contribute to the disease deterioration. Case report of COVID-19 against the background of AA-amyloidosis is presented due to the relevance of the problem. Patient G.G., 63 years old, on 20.02.2023 yr. for a few hours was in inpatient treatment in Cheboksary district hospital. She was admitted in critical condition. Her complaints (according to relatives) were cough, dyspnea and fever up to 38.3 ^○C. On arrival at the hospital: diminished breath sounds in posterior and inferior lung segments and fine crackles on chest auscultation were identified. Blood pressure was 110/60 mmHg. Liver was 2 cm below the edge of the rib arch. Coronavirus infection test, performed by the polymerase chain reaction method, was positive. Laboratory data showed white blood cell in amount of 21.3 (4—9)·10⁹/L, lymphocytes — 6 (19—37)%, ESR — 78.00 mm/h, blood urea nitrogen — 37.5 (2.8—8.3) mmol/L and creatinine — 247.0 (62.0—120.0) mcmol/L. Treatment was initiated, and then suddenly fatal outcome was registered. On autopsy examination, features of COVID-associated pneumonitis and alveolitis in lungs were revealed. Amyloid masses deposition and centrolobular cell necrosis were found in the liver. There were signs of acute kidney injury apart from vascular amyloidosis in the kidneys. The cause of death was a new coronavirus infection, COVID-19, complicated by COVID-associated pneumonitis, alveolitis and acute respiratory distress syndrome in adults. Presence of comorbid diseases, specifically AA-amyloidosis of liver and kidneys, aggravated the disease course and led to development of multiple organ failure.